US RE29607 E
Compounds of the formula ##STR1## in which R is H, .[.Cl, F, CH3 or CF3 .]. .Iadd.m-F, p-F, o-F, p-Cl, p-CH3, m-CH3 or m-CF3 .Iaddend.. The compounds are prepared by cyclizing with ethyl carbonate, a compound of the formula ##STR2## The compounds have anti-depressive, myorelaxing, tranquilizing, sedative, analgesic, anti-convulsive, anti-pyretic, anti-inflammatory and uricosuric activities.
The present invention concerns novel derivatives of 5-hydroxymethyl-3-substituted-2-oxazolidinones, their process of preparation and their therapeutic application.
The compounds according to the present invention correspond to the general formula: ##STR3## in which R represents .[.a hydrogen atom, a halogen atom, an alkyl radical having 1 to 4 carbon atoms or a trifluoromethyl radical..]. .Iadd.m-F, p-F, o-F, p-Cl, p-CH3, m-CH3 or m-CF3. .Iaddend.
The process for the preparation of the compounds according to the present invention comprises cyclising, by the action of ethyl carbonate, a 1-phenylamino-2,3-propanediol of the general formula: ##STR4## in which R has the same significance as in Formula I.
The following preparation is given, by way of non-limitative example, to illustrate the present invention.
59 G. OF 1-(M-TRIFLUOROMETHYL PHENYLAMINO)-2,3-PROPANEDIOL AND 118 G. OF ETHYL CARBONATE ARE INTRODUCED INTO A DISTILLATION APPARATUS. The mixture is progressively heated to about 110° C. when dissolution is obtained. Then, 12 ml. of a 5% solution of sodium methylate in methanol is added thereto. The distillation of the ethanol formed during the course of the reaction is then observed. Upon completion thereof any excess ethyl carbonate is removed under reduced pressure and the residue obtained is crystallized in isopropyl ether.
Melting point=80° C.
Empirical formula=C11 H10 F3 NO3
Elementary analysis.--Calculated percent: C, 50.58; H, 3.86; N, 5.36. Found percent: C, 50,74; H, 3.76; N, 5.56.
The compounds listed in the following table have been prepared according to the process of the above example:
TABLE I__________________________________________________________________________ ##STR5## Elementary analysis, percent Empirical Mol M.P. Yield, Calculated FoundCode No.R formula wt. ° C. percent C H N C H N__________________________________________________________________________67360H C10 H11 NO3 192.20 129 75 62.16 5.74 7.25 62.20 5.87 7.4068292m-F C10 H10 FNO3 211.19 96 87 56.87 4.77 6.63 56.88 4.92 6.7969155p-F C10 H10 FNO3 211.19 116 68 56.87 4.77 6.63 56.97 4.77 6.8369275o-F C10 H10 FNO3 211.19 94 60 56.87 4.77 6.63 56.75 4.73 6.676922 p-Cl C10 H10 ClNO3 227.64 104 55 52.75 4.43 6.15 53.01 4.53 6.0569204p-CH3 C11 H13 NO3 207.22 145 66 63.75 6.32 6.76 63.93 6.10 6.8869276m-CH.sub. 3 C11 H13 NO3 207.22 76 70 63.75 6.32 6.76 63.70 6.43 6.78.[. 9217o-CH3 C11 H13 NO3 207.22 64 69 63.75 6.32 6.76 63.71 6.37 6.88.].__________________________________________________________________________
The compounds of Formula I experimentally exert anti-depressive. myorelaxing, tranquillising, sedative, analgesic, anti-convulsive, anti-pyretic, anti-inflammatory and uricosuric activities. Moreover, their toxic effects on animals in the laboratory are little marked.
(1) Anti-depressive properties.--The compounds of Formula I are capable of opposing hypothermia and the ptosis provoked by reserpine in the rat and the mouse, as well as the ulcers provoked by reserpine in the rat. Moreover, they oppose the catalepsy provoked by prochlorperazine in the rat.
By way of example, several results obtained are listed in the following table:
TABLE II__________________________________________________________________________ PtosisHypothermia Rat Mouse Ulcers Effect, Effect, Effect, Effect,Code No. Dose1 ° C. Dose1 percent Dose1 percent Dose1 percent__________________________________________________________________________67360 200 -3.3 200 70 200 55 -- --68121 100 -3.3 -- -- 100 45 100 7768292 100 -2.6 100 75 100 50 100 856922 -- -- 100 45 100 55 -- --69201 100 -2.9 -- -- -- -- -- --69276 -- -- -- -- -- -- 100 50__________________________________________________________________________ 1 Expressed in mg./kg./p.o.
(II) Myorelaxing properties.--The compounds of Formula I provoke in the mouse the loss of the righting reflex and inhibit the traction reflexes and the maintenance on a rotating rod.
By way of example, the results obtained with two compounds of Formula I are listed in the following table:
TABLE III______________________________________ Rotating rodCode No. Traction test, ED50 test, ED50______________________________________67360 300 mg./kg./p.o. 160 mg./kg./p.o.68121 110 mg./kg./p.o.______________________________________
(III) Tranquillising and sedative action.--These effects are shown by a diminution of exploration curiosity in the enclose of an actimetric cage and of escape in an open field. The compound of Formula I reduce the aggressiveness provoked in the passage of an electric current and lower the body temperature of animals. The narcotic effects of penthiobarbital are equally reinforced.
The results obtained with two compounds of Formula I are listed in the following table:
TABLE IV______________________________________ PotentialisationActimetric cage Evasion test penthiobarbital Effect, Effect, Effect,Code No. Dose1 percent Dose1 percent Dose1 percent______________________________________67360 90 50 200 70 200 8068121 100 70 -- -- 80 50______________________________________ 1 Expressed in mg./kg./p.o.
(IV) Analgesic activity.--This activity is particularly pronounced against the painful stretching provoked in the mouse by the intraperitoneal administration of phenyl benzoquinone or acetic acid.
The results obtained with two compounds of Formula I are shown in the following table:
TABLE V______________________________________ Protection against phenylbenzoquinone Dose in Effect,Code No. mg./kg./p.o. percent______________________________________67360 90 5068121 45 50______________________________________
(V) Anti-convulsive properties.--The compounds of Formula I exert in the mouse an antagonism against the lethal effects of cardiazol, strychnine and nicotine. They equally show activity against the tonic hyperextension of an excessive electric shock.
By way of example, the results obtained with several compounds of Formula I are listed in the following table:
TABLE VI______________________________________ Antagonism against Cardizol Strychnine Nicotine Effect, Effect, Effect,Code No. Dose1 percent Dose1 percent Dose1 percent______________________________________67360 -- -- 140 50 -- --68121 120 50 100 50 100 8068292 -- -- 100 70 100 606922 -- -- 100 100 -- --69155 -- -- 100 65 -- --______________________________________ 1 Expressed in mg./kg./p.o.
(VI) Anti-pyretic action.--This action is manifested by a diminution of the experimental fever provoked by the administration of barm in the cat.
(VII) Anti-inflammatory effect.--The under-plantar oedema provoked in the rat by the administration of carraghenine is diminished by the compounds of the present invention.
(VIII) Uricosuric action.--After repeated oral administration in the rat, the compounds of Formula I provoke an augmentation of the urinary eliminations of uric acid.
In consequence of the results shown above, and the values appearing in the following table, the difference between the pharmacologically-active dose and the lethal dose is sufficiently great to enable the compounds of Formula I to be utilised in therapeutics.
TABLE VII______________________________________Code No. LD50 P.O. (mouse,) mg./kg.______________________________________67360 >160068121 140068292 15006922 105069155 120069204 >400069276 1850______________________________________
The compounds of Formula I are indicated in the case of depression and neurosis by depressive and anxious components. They equally possess a favourable effect against contractural and inflammatory pains, with or without hyperthermia.
They may be administered in the form of tablets and gelules containing 50 to 250 mg. of active ingredient.
Hence, according to the present invention there is also provided a therapeutic composition comprising a compound of Formula I together with a therapeutically-acceptable carrier.